Vycor Medical Reports Net Income of $20,108 in Q1 2026, Significant Turnaround from Previous Year

Vycor Medical, Inc. reported a net income of $20,108 for the first quarter of 2026, a significant turnaround from a net loss of $38,563 in the same period of 2025. The company generated revenues of $458,540, reflecting a 5% increase from $436,378 year-over-year. This growth was primarily driven by a 5% increase in sales from its Vycor Medical segment, which reported revenues of $440,441, while NovaVision contributed $18,099, a modest 1% increase. The gross profit for the quarter was $375,153, up from $358,534 in the prior year, maintaining a gross margin of approximately 82%.

In terms of operational efficiency, Vycor Medical reduced its total operating expenses to $329,345 from $371,340, a decrease of 11%. Notably, research and development expenses were eliminated in the current quarter, down from $5,762 in 2025. Selling, general, and administrative expenses also saw a reduction, decreasing by $35,333 to $315,365, largely due to a decrease in stock-based compensation and sales commissions. The company reported an operating income of $45,808, a significant improvement from an operating loss of $12,806 in the previous year.

The company’s balance sheet showed total assets of $854,071 as of March 31, 2026, compared to $830,420 at the end of 2025. Current assets increased to $651,047, driven by a rise in cash holdings to $173,634 from $86,982. However, Vycor continues to face a working capital deficiency of $4,297,001, which includes substantial related party liabilities. This situation raises concerns about the company's ability to continue as a going concern, as it has incurred losses since inception and has not generated sufficient positive cash flows from operations.

Geographically, Vycor Medical's revenue was predominantly generated in the United States, amounting to $455,705, while European sales were minimal at $2,835. The company is focusing on increasing its market penetration in the U.S. and expanding internationally. The strategic plan includes new product development and potential partnerships to enhance distribution capabilities. The company is also exploring options for additional funding to support its operations and growth initiatives, although there is no assurance that such funding will be available on favorable terms.

Looking ahead, Vycor Medical aims to continue its revenue growth strategy while addressing its liquidity challenges. The company is executing a plan to reduce operating losses and may consider seeking additional equity or debt funding. However, the uncertainty surrounding its ability to secure necessary funds could impact its operational capabilities and product development timelines.